GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Phoenix Biotech Acquisition Corp (NAS:PBAX) » Definitions » Shares Outstanding (EOP)

Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Shares Outstanding (EOP) : 6.25 Mil (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Phoenix Biotech Acquisition Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Phoenix Biotech Acquisition's shares outstanding for the quarter that ended in Sep. 2023 was 6.25 Mil.

Phoenix Biotech Acquisition's quarterly shares outstanding declined from Jun. 2023 (6.77 Mil) to Sep. 2023 (6.25 Mil). It means Phoenix Biotech Acquisition bought back shares from Jun. 2023 to Sep. 2023 .

Phoenix Biotech Acquisition's annual shares outstanding declined from Dec. 2021 (22.98 Mil) to Dec. 2022 (6.77 Mil). It means Phoenix Biotech Acquisition bought back shares from Dec. 2021 to Dec. 2022 .


Phoenix Biotech Acquisition Shares Outstanding (EOP) Historical Data

The historical data trend for Phoenix Biotech Acquisition's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phoenix Biotech Acquisition Shares Outstanding (EOP) Chart

Phoenix Biotech Acquisition Annual Data
Trend Dec21 Dec22
Shares Outstanding (EOP)
22.98 6.77

Phoenix Biotech Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.98 6.77 6.77 6.77 6.25

Competitive Comparison of Phoenix Biotech Acquisition's Shares Outstanding (EOP)

For the Shell Companies subindustry, Phoenix Biotech Acquisition's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phoenix Biotech Acquisition's Shares Outstanding (EOP) Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Phoenix Biotech Acquisition's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Phoenix Biotech Acquisition's Shares Outstanding (EOP) falls into.



Phoenix Biotech Acquisition Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Phoenix Biotech Acquisition  (NAS:PBAX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Phoenix Biotech Acquisition Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Phoenix Biotech Acquisition's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
2201 Broadway, Suite 705, Oakland, CA, USA, 94612
Website
Phoenix Biotech Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company intends to pursue an acquisition opportunity in any business, industry, sector or geographical location, industries that complement management team's background, and to capitalize on the ability of management team to identify and acquire a business in the healthcare or healthcare related industries in the United States and Europe.
Executives
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kathleen Laporte director
Christopher B Ehrlich director, 10 percent owner, officer: CEO and and Secretary 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Douglas Fisher officer: President 587 PATROL RD, WOODSIDE CA 94062
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Phoenix Biotech Sponsor, Llc 10 percent owner 2001 MARKET STREET, SUITE 3400, PHILADELPHIA PA 19103